In patients treated with dialysis, FGF-23 thus appears to have a significant role as a biomarker that predicts some aspects of the abnormalities of bone metabolism that are observed in this condition and are part of the spectrum of metabolic bone disease (MBD) associated with CKD.(60). The gene discussed is FGF23; the disease is chronic kidney disease.